As the only park in Chongqing that has been included in the first national strategic emerging industrial cluster development project, Chongqing International Biological City will focus on building a leading biomedicine industry chain in western China, striving to be an international biomedicine city with global influence in the upper reaches of the Yangtze River.

Introduced by a director of the biological city, biomedicine has become the fastest growing industry worldwide, with wide coverage, a long industry chain, and great growth potential. Driven by the city's strategy of biomedicine industry cluster area, CIBC has gathered more than 80 biomedicine companies, including ten under the clinical trial phase of original new drugs, accounting for nearly 50% of the city's total.

In order to drive the national biomedicine industry clusters, the biological city will make greater efforts to support the innovation in the biomedicine industry during the 14th Five-Year Plan by improving the industry chain, introducing more biomedicine companies, enhancing brand value, and tapping new areas of economic growth.

Enhancing innovation capability, the biological city will reinforce the innovation platform for biomedicine companies, universities, and research institutions, strengthen the innovation chain and capabilities for original innovation, and build Chongqing International Institute for Immunology into China's leading platform for immune research and development and achievement transformation with international influence.

Moreover, strengthening factor guarantee, the biological city will expand industry funds, improve service environment and infrastructure, help biomedicine companies solve their difficulties in finance, supply, and logistics, improve the business environment, provide district-based and one-to-one services and the whole-process tracking service without the second visit for companies.

According to the planning, by 2025, the biological city will strive to achieve its total industrial output value above the designated size of more than 50 billion yuan (about 7.6 billion U.S. dollars), including the output value of drugs of more than 35 billion yuan. By then, some knock-out products such as HPV vaccines, oral paclitaxel, long-acting insulin, and monoclonal antibodies will be put into production on the market.